naproxen has been researched along with thromboxane a2 in 9 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (thromboxane a2) | Trials (thromboxane a2) | Recent Studies (post-2010) (thromboxane a2) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 5,617 | 224 | 429 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dandona, P; Jeremy, JY | 1 |
| Barradas, MA; Dandona, P; Jeremy, JY; Kirk, RM; Mikhailidis, DP | 1 |
| Gréen, K; Vesterqvist, O | 1 |
| Buchanan, WW; Butt, R; Howard-Lock, H; Kean, WF; Lock, CJ; Rischke, J | 1 |
| Freeman, D; Lamki, L; McDonald, JW; Spence, JD; Wong, DG | 1 |
| Vane, JR | 1 |
| Frankish, H | 1 |
| Fitzgerald, GA | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
1 trial(s) available for naproxen and thromboxane a2
| Article | Year |
|---|---|
Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.
Topics: 6-Ketoprostaglandin F1 alpha; Adrenergic beta-Antagonists; Adult; Amiloride; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Indenes; Male; Middle Aged; Naproxen; Piroxicam; Random Allocation; Sulindac; Thiazines; Thromboxane A2; Timolol | 1986 |
8 other study(ies) available for naproxen and thromboxane a2
| Article | Year |
|---|---|
Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastric Mucosa; Humans; Indomethacin; Male; Nabumetone; Naproxen; Platelet Aggregation; Platelet Aggregation Inhibitors; Prodrugs; Prostaglandins; Rats; Rats, Inbred Strains; Thromboxane A2 | 1990 |
The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Topics: 6-Ketoprostaglandin F1 alpha; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Butanones; Culture Techniques; Dinoprostone; Epoprostenol; Gastric Mucosa; Humans; Indomethacin; Nabumetone; Naphthaleneacetic Acids; Naproxen; Platelet Aggregation; Thromboxane A2; Thromboxane B2 | 1990 |
Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Epoprostenol; Female; Humans; Male; Naproxen; Thromboxane A2; Thromboxane B2 | 1989 |
Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets.
Topics: Collagen; Female; Humans; In Vitro Techniques; Male; Naproxen; Platelet Aggregation; Platelet Aggregation Inhibitors; Stereoisomerism; Thromboxane A2; Thromboxanes | 1989 |
Biomedicine. Back to an aspirin a day?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotid Artery Injuries; Cell Division; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Homeostasis; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Muscle, Smooth, Vascular; Myocardial Infarction; Naproxen; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfones; Thromboxane A2 | 2002 |
Why do COX-2 inhibitors increase risk of cardiovascular events?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Myocardial Infarction; Naproxen; Prostaglandin-Endoperoxide Synthases; Sulfones; Thromboxane A2 | 2002 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |